SGLT2 inhibitors in acute myocardial infarction: what can we learn from the DAPA-MI trial? More news from American Heart Association Scientific Meeting

DAPA-MI, a registry-based randomized trial presented at AHA 2023, examined the question regarding use of Sodium-glucose cotransporter-2 ( SGLT2) inhibitors in patients with acute myocardial infarction ( MI) . SGLT2 inhibitors: pioneering c ha nge in t reat ment pa radigmsSGLT2 inhibitors, initially developed as anti-diabetes drugs, have emerged as key Class 1 drugs in the management of patients with heart failure ( HF) over a broad spectrum of left ventricular ejection fraction ( EF) . 1 -3 A sub-analysis of the DECLARE-TIMI 58 trial showed that dapagliflozin reduces major adverse cardiac events ( MACE) and the composite of cardiovascular ( CV) death or hospitalization for heart failure ( HHF) in patients with type 2 diabetes mellitus ( T2DM) and a history of MI, 4 , 5 which prompted further investigation into the potential benefits of dapagliflozin in a wider group of patients with acute MI.